The identification work revealed that two of the biomarkers are acute phase proteins (APPs). Although APPs have been investigated in veterinary medicine for some time, we have continued our unique multi-marker approach to develop specific analytical algorithms which combine the relative levels of both haptoglobin and C Reactive Protein in serum. Combining the APPs by using algorithms has dramatically improved the performance of the biomarkers when measured by themselves. This has enabled us to develop the Advanced Lymphoma Blood Test (ALBT), which has numerous benefits over the original LBT.

We have tested the ALBT with 194 rigorously followed up diagnostic samples consisting of lymphoma samples and samples from dogs with benign lymphoid hyperplasia and other diseases with similar presentations to lymphoma.